Breaking News Instant updates and real-time market news.

AGIO

Agios Pharmaceuticals

$91.06

-0.23 (-0.25%)

, CELG

Celgene

$85.09

-0.26 (-0.30%)

20:07
07/22/18
07/22
20:07
07/22/18
20:07

Agios' Tibsovo approved earlier, launch should go well, says Piper Jaffray

Piper Jaffray analyst Tyler Van Buren notes that Agios (AGIO) announced the FDA approval of Tibsovo for relapsed/refractory acute myeloid leukemia, which represents the company's second approved drug product within the past year. The analyst points out that both Tibsovo and Idhifa, which was approved August 2017, cover approximately 20% of all AML patients who harbor IDHm mutations. Due to partner Celgene (CELG) and Agios' existing Idhifa launch efforts and the strong awareness of and similarity between both products, Van Buren expects the Tibsovo launch to be as good as - if not better - than the early Idhifa launch. Over time, he believes that Tibsovo can treat the majority of U.S; AML patients with IDH1 mutations and generate sales approaching $150M. The analyst reiterates an Overweight rating and $125 price target on Agios shares.

AGIO

Agios Pharmaceuticals

$91.06

-0.23 (-0.25%)

CELG

Celgene

$85.09

-0.26 (-0.30%)

  • 26

    Jul

  • 21

    Aug

AGIO Agios Pharmaceuticals
$91.06

-0.23 (-0.25%)

05/23/18
SBSH
05/23/18
INITIATION
Target $117
SBSH
Buy
Citi starts Agios with Buy rating, $117 price target
Citi analyst Mohit Bansal started Agios Pharmaceuticals with a Buy rating and $117 price target. Agios is a "unique" company with the potential to have multiple products on markets in next three years, Bansal tells investors in a research note. He believes the company has a "substantial opportunity" with its metabolic oncology and rare disease pipeline. The analyst has a "bull case" valuation of $170-$180 per share and takeover valuation of $180-$200 per share.
05/30/18
PIPR
05/30/18
INITIATION
Target $125
PIPR
Overweight
Agios Pharmaceuticals initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren started Agios Pharmaceuticals with an Overweight rating and $125 price target. The analyst believes both Idhifa and Tibsovo will experience commercial success while AG-348 for pyruvate kinase deficiency could represent a $750M-plus opportunity. He sees "no shortage of potential opportunities for future value creation."
06/04/18
JPMS
06/04/18
NO CHANGE
JPMS
Overweight
JPMorgan says Agios data reinforces additive benefit potential of ivosidenib
JPMorgan analyst Anupam Rama said updates from the phase 1b trial center on the ivosidenib combination arm includes an incremental increase in ORR and in-line CR rates with larger patient dataset, which reinforces his view of the potential for meaningful additive benefit from IDH inhibition on top of azacitidine. Rama added that he did not see any major incremental safety concerns in the data. Rama has an Overweight rating on Agios shares, which are down nearly 11% in morning trading.
06/04/18
PIPR
06/04/18
NO CHANGE
PIPR
Overweight
Agios' ivosidenib combo data support use in frontline AML, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren noted that the combo of ivosidenib plus Vidaza demonstrated "robust" clinical activity, including the rough doubling of ORR and CR rates compared to Vidaza monotherapy, and he believes the data shared at ASCO are supportive of the combination being used in the frontline AML setting. If these earlier trial results are replicated in the AGILE Phase 3 study, Van Buren sees a high probability of this combo being approved and used in the frontline AML setting, he tells investors. He maintains an Overweight rating on shares of Agios Pharmaceuticals, which are down 5% to $91.92 in afternoon trading.
CELG Celgene
$85.09

-0.26 (-0.30%)

07/10/18
PIPR
07/10/18
NO CHANGE
PIPR
Neutral
Celgene raised prices on both Revlimid and Pomalyst by 5%, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond noted that Wolters Kluwer Health reports that Celgene increased its prices for Revlimid and Pomalyst by 5%, effective yesterday. The analyst, who pointed out that this is the first increase since October 2017 for both drugs, said the price hikes should provide some tailwind to Celgene's second half results. He maintains his Neutral rating on Celgene shares.
07/11/18
PIPR
07/11/18
NO CHANGE
Target $365
PIPR
Overweight
Biogen price target raised to $365 from $353 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for Biogen (BIIB) to $365 saying a survey of 101 neurologists gives him increased confidence in the staying power of the company's multiple sclerosis franchise. Tecfidera market share "edged up slightly" during the quarter, and the survey shows signs of Roche's (RHHBY) Ocrevus "hitting a bit of a wall," Raymond tells investors in a research note. Further, the analyst continues to hear feedback that Celgene's (CELG) ozanimod "will be minimally differentiated." Despite increased signs of payer activism in the space, Biogen's MS franchise is well positioned for the near-to-intermediate term, Raymond contends. He raised his estimates for Tecfidera and keeps an Overweight rating on Biogen.
07/11/18
ADAM
07/11/18
NO CHANGE
Target $140
ADAM
Buy
Celgene's Buy rating backed at Canaccord following Phase 3 Impassion130 results
Canaccord analyst John Newman maintained a Buy rating and $140 price target on Celgene (CELG) after the company said that the Phase 3 Impassion130 study showed progression-free survival, or PFS, improvement for 1L metastatic or unresectable triple negative breast cancer with Abraxane plus Tecentriq (RHHBY) , which opens the door to Tencentriq in this indication. In a research note to investors, Newman says he expects continued upside from pipeline advances and diversification based on in-licensing, M&A and organic R&D and that, as there are currently no alternatives to chemotherapy, the combination of Abraxane plus Tecentriq should see widespread use if approved. He views the advances in TNBC "very positively" given the high unmet need for viable therapy.
07/12/18
PIPR
07/12/18
NO CHANGE
Target $95
PIPR
Neutral
PTAB decision on Gilenya positive for Celgene, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond expects the market to react positively with respect to Celgene (CELG) shares, at least initially, following the Patent Trial and Appeal Board decision regarding ozanimod competitor Gilenya from Novartis (NVS). Yesterday, the PTAB issued a decision that upholds validity of Gilenya's dosing patent in response to inter partes review petitions from multiple generic filers, Raymond tells investors in a research note. While this decision will likely be appealed, it opens up the possibility for Gilenya intellectual property runway out to 2027, when the dosing patent expire, the analyst adds. Raymond believes that not having a generic S1P class at launch for ozanimod is positive for Celgene. However, without the removal of first dose monitoring, ozanimod is not likely to be differentiated enough to make a difference, the analyst says, citing physician feedback. He keeps a Neutral rating on Celgene with a $95 price target. The stock in early trading is up 2% to $84.92.

TODAY'S FREE FLY STORIES

SAIL

SailPoint

$24.30

-1.24 (-4.86%)

20:39
11/12/18
11/12
20:39
11/12/18
20:39
Upgrade
SailPoint rating change  »

SailPoint upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 09

    Jan

ALB

Albemarle

$98.05

-4.35 (-4.25%)

20:32
11/12/18
11/12
20:32
11/12/18
20:32
Periodicals
Breaking Periodicals news story on Albemarle »

Albemarle request for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

KORS

Michael Kors

$47.75

-0.04 (-0.08%)

20:30
11/12/18
11/12
20:30
11/12/18
20:30
Initiation
Michael Kors initiated  »

Michael Kors initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

TPR

Tapestry

$41.28

-0.71 (-1.69%)

20:29
11/12/18
11/12
20:29
11/12/18
20:29
Initiation
Tapestry initiated  »

Tapestry initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

AMZN

Amazon.com

$1,636.70

-75.73 (-4.42%)

20:26
11/12/18
11/12
20:26
11/12/18
20:26
Hot Stocks
Amazon.com launches 2nd GovCloud region in the U.S. »

Amazon Web Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 28

    Nov

  • 04

    Dec

FHN

First Horizon

$16.09

-0.22 (-1.35%)

20:08
11/12/18
11/12
20:08
11/12/18
20:08
Upgrade
First Horizon rating change  »

First Horizon upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TI

Telecom Italia

$6.01

0.09 (1.52%)

20:04
11/12/18
11/12
20:04
11/12/18
20:04
Periodicals
Telecom Italia board to meet on Tuesday to consider CEO ouster, Bloomberg says »

The board of Telecom…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$117.47

-2.065 (-1.73%)

, COP

ConocoPhillips

$65.20

-1.54 (-2.31%)

19:58
11/12/18
11/12
19:58
11/12/18
19:58
Periodicals
Exxon Mobil, Chevron, Conoco considering bid for Endeavor Energy, Bloomberg says »

Chevron (CVX_, Exxon…

CVX

Chevron

$117.47

-2.065 (-1.73%)

COP

ConocoPhillips

$65.20

-1.54 (-2.31%)

XOM

Exxon Mobil

$79.87

-1.01 (-1.25%)

RDS.A

Royal Dutch Shell

$62.16

-0.84 (-1.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 26

    Nov

ATTO

Atento

$5.96

0.075 (1.28%)

19:00
11/12/18
11/12
19:00
11/12/18
19:00
Earnings
Atento reports Q3 recurring EPS 25c, consensus 20c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 15

    Nov

VKTX

Viking Therapeutics

$11.73

-0.605 (-4.91%)

18:57
11/12/18
11/12
18:57
11/12/18
18:57
Hot Stocks
Viking Therapeutics says VK2809 study achieves primary, secondary endpoints »

Viking Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

KEX

Kirby

$74.20

-1.83 (-2.41%)

18:31
11/12/18
11/12
18:31
11/12/18
18:31
Hot Stocks
Kirby to acquire CGBM's inland tank barge fleet, terms not disclosed »

Kirby announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

HUYA

Huya

$18.50

-0.5 (-2.63%)

, MFIN

Medallion Financial

$6.80

-0.23 (-3.27%)

18:31
11/12/18
11/12
18:31
11/12/18
18:31
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Huya…

HUYA

Huya

$18.50

-0.5 (-2.63%)

MFIN

Medallion Financial

$6.80

-0.23 (-3.27%)

EB

Eventbrite

$30.90

-1.6 (-4.92%)

YRD

Yirendai

$15.47

-1.75 (-10.16%)

KRNT

Kornit Digital

$19.15

-0.88 (-4.39%)

MHLD

Maiden Holdings

$2.40

-1.12 (-31.82%)

SAGE

Sage Therapeutics

$121.50

-9.46 (-7.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 14

    Nov

  • 27

    Nov

  • 19

    Dec

OMAB

OMA Airports

$40.18

0.41 (1.03%)

18:18
11/12/18
11/12
18:18
11/12/18
18:18
Hot Stocks
OMA Airports names Ricardo Duenas as new CEO »

The board of OMA approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEUM

Pareteum

$2.13

-0.09 (-4.05%)

, IPAS

iPass

$1.14

(0.00%)

18:03
11/12/18
11/12
18:03
11/12/18
18:03
Hot Stocks
Pareteum to acquire iPass in all-stock transaction »

Pareteum (TEUM) and iPass…

TEUM

Pareteum

$2.13

-0.09 (-4.05%)

IPAS

iPass

$1.14

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

NINE

Nine Energy Services

$33.58

-1.6 (-4.55%)

18:01
11/12/18
11/12
18:01
11/12/18
18:01
Earnings
Nine Energy Service reports Q3 EPS 56c, consensus 56c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

TEUM

Pareteum

$2.13

-0.09 (-4.05%)

, IPAS

iPass

$1.14

(0.00%)

18:00
11/12/18
11/12
18:00
11/12/18
18:00
Hot Stocks
Breaking Hot Stocks news story on Pareteum, iPass »

Pareteum to acquire iPass…

TEUM

Pareteum

$2.13

-0.09 (-4.05%)

IPAS

iPass

$1.14

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

BMWYY

BMW

$0.00

(0.00%)

17:57
11/12/18
11/12
17:57
11/12/18
17:57
Periodicals
BMW in talks to sell branded credit-card unit, Bloomberg says »

BMW is held talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$189.37

-16.25 (-7.90%)

17:54
11/12/18
11/12
17:54
11/12/18
17:54
Hot Stocks
Nvidia reports record adoption of new Turing T4 GPU »

Nvidia announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 26

    Nov

  • 10

    Dec

GLD

SPDR Gold Trust

$113.66

-0.82 (-0.72%)

17:51
11/12/18
11/12
17:51
11/12/18
17:51
Hot Stocks
SPDR Gold Trust holdings rise to 762.00MT from 755.23MT »

This is the highest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$331.15

-19.54 (-5.57%)

17:45
11/12/18
11/12
17:45
11/12/18
17:45
Periodicals
Tesla legal executive with regulatory experience leaving, Bloomberg says »

Amid a recent fraud…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 19

    Nov

  • 13

    Dec

HUYA

Huya

$18.50

-0.5 (-2.63%)

17:34
11/12/18
11/12
17:34
11/12/18
17:34
Hot Stocks
Huya reports Q3 average mobile MAUs 49.4M, up 28.2% from last year »

Q3 Average MAUs reached…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

VLKAY

Volkswagen

$0.00

(0.00%)

, DDAIF

Daimler AG

$0.00

(0.00%)

17:34
11/12/18
11/12
17:34
11/12/18
17:34
Periodicals
Trump close to auto tariffs in a move that may have 'massive' fallout, BI says »

According to Business…

VLKAY

Volkswagen

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$115.48

-1.83 (-1.56%)

F

Ford

$9.49

0.11 (1.17%)

HMC

Honda

$28.16

-0.34 (-1.19%)

GM

General Motors

$35.71

0.01 (0.03%)

FCAU

Fiat Chrysler

$15.78

-0.48 (-2.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 14

    Nov

  • 13

    Dec

MPVD

Mountain Province Diamonds

$1.42

-0.03 (-2.07%)

17:32
11/12/18
11/12
17:32
11/12/18
17:32
Earnings
Mountain Province Diamonds reports Q3 EPS 8c, one estimate 6c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

HUYA

Huya

$18.50

-0.5 (-2.63%)

17:32
11/12/18
11/12
17:32
11/12/18
17:32
Earnings
Breaking Earnings news story on Huya »

Huya sees Q4 revenue up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

YY

YY

$61.39

-3.34 (-5.16%)

17:32
11/12/18
11/12
17:32
11/12/18
17:32
Earnings
Breaking Earnings news story on YY »

YY sees Q4 revenue growtn…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.